Centocor, Inc. Releases Phase 2 Data On Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis

Thu, 08 Feb 2007 02:00 PM EST

... Phase 2 data published today in the New England Journal of Medicine showed that patients with moderate to severe plaque psoriasis receiving subcutaneous injections of CNTO 1275 (IL-12/23 mAb) experienced significant clearance of skin disease and significant improvements in quality of life. [click link for full article] ...